Home
/ AbbVie
/ Financials & Metrics

AbbVie (ABBV) stock price, revenue, and financials

AbbVie market cap is $206.1 b, and annual revenue was $45.8 b in FY 2020

View Company

+4.9(+4.19%)

$206.1 B

ABBV Mkt cap, 12-Nov-2021

$14 B

AbbVie Revenue Q2, 2021

AbbVie Gross profit (Q2, 2021)9.4 B

AbbVie Gross profit margin (Q2, 2021), %67.6%

AbbVie Net income (Q2, 2021)769 M

AbbVie EBIT (Q2, 2021)4.4 B

AbbVie Cash, 30-Jun-20218.5 B

AbbVie EV279.7 B

AbbVie Revenue

AbbVie revenue was $45.8 b in FY, 2020 which is a 37.7% year over year increase from the previous period.

Embed Graph

AbbVie Revenue Breakdown

Geographic Segment

Embed Graph

AbbVie revenue breakdown by geographic segment: 23.9% from International and 76.1% from United States

Annual

USD	FY, 2016	FY, 2017	FY, 2018	FY, 2019	FY, 2020
Revenue	25.6b	28.2b	32.8b	33.3b	45.8b
Revenue growth, %	12%	10%	16%	2%	38%
Cost of goods sold	5.8b	7.0b	7.7b	7.4b	15.4b
Gross profit	19.8b	21.2b	25.0b	25.8b	30.4b
Gross profit Margin, %	77%	75%	76%	78%	66%
R&D expense	4.4b	5.0b	10.3b	6.4b	6.6b
General and administrative expense	5.9b	6.3b	7.4b	6.9b	11.3b
Operating expense total	10.4b	11.6b	18.7b	13.3b	19.1b
EBIT	9.4b	9.6b	6.4b	13.0b	11.4b
EBIT margin, %	37%	34%	19%	39%	25%
Interest expense	965.0m	1.0b	1.1b	1.5b	2.3b
Pre tax profit	7.9b	7.7b	5.2b	8.4b	3.4b
Income tax expense	1.9b	2.4b	(490.0m)	544.0m	(1.2b)
Net Income	6.0b	5.3b	5.7b	7.9b	4.6b
EPS	3.6	3.3	3.7	5.3	2.7

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021
Revenue	6.5b	6.9b	7.0b	7.9b	8.3b	8.2b	7.8b	8.3b	8.5b	8.6b	10.4b	12.9b	13.0b	14.0b
Cost of goods sold	1.6b	1.5b	1.6b	1.9b	1.9b	1.8b	1.7b	1.8b	1.9b	1.9b	3.7b	5.1b	4.2b	4.5b
Gross profit	4.9b	5.4b	5.4b	6.0b	6.3b	6.4b	6.1b	6.4b	6.6b	6.7b	6.7b	7.9b	8.8b	9.4b
Gross profit Margin, %	75%	78%	77%	76%	77%	78%	78%	78%	77%	77%	64%	61%	68%	68%
R&D expense	1.1b	1.2b	1.2b	1.2b	1.3b	1.3b	1.3b	1.3b	2.3b	1.4b	1.6b	1.7b	1.8b	1.8b
General and administrative expense	1.4b	1.5b	1.5b	1.8b	1.8b	1.9b	1.7b	1.7b	1.7b	1.7b	3.5b	2.8b	2.8b	3.2b
Operating expense total	2.5b	2.7b	2.7b	3.1b	3.6b	3.2b	3.1b	3.0b	3.9b	3.1b	6.0b	4.6b	4.7b	5.0b
EBIT	2.4b	2.7b	2.7b	2.9b	2.8b	3.2b	3.0b	3.4b	2.6b	3.6b	752.0m	3.3b	4.1b	4.4b
EBIT margin, %	37%	39%	39%	37%	33%	38%	38%	41%	31%	42%	7%	25%	32%	32%
Interest expense	247.0m	253.0m	252.0m	251.0m	272.0m	302.0m	325.0m	309.0m	420.0m	428.0m	614.0m	620.0m	622.0m	606.0m
Pre tax profit	2.1b	2.4b	2.1b	2.8b	2.0b	2.8b	2.5b	807.0m	2.0b	3.1b	(693.0m)	2.5b	3.9b	1.2b
Income tax expense	375.0m	438.0m	464.0m	14.0m	29.0m	14.0m	88.0m	66.0m	117.0m	88.0m	46.0m	187.0m	312.0m	394.0m
Net Income	1.7b	1.9b	1.6b	2.8b	2.0b	2.7b	2.5b	741.0m	1.9b	3.0b	(739.0m)	2.3b	3.6b	769.0m
EPS	1.1	1.2	1.0	1.7	1.3	1.8	1.7	0.5	1.3	2.0	(0.5)	1.3	2.0	0.4

Annual

USD	FY, 2016	FY, 2017	FY, 2018	FY, 2019	FY, 2020
Cash	5.1b	9.3b	7.3b	39.9b	8.4b
Accounts Receivable	4.8b	5.1b	5.4b	5.4b	8.8b
Prepaid Expenses	3.6b	4.7b	1.9b	2.4b	3.6b
Inventories	1.4b	1.6b	1.6b	1.8b	3.3b
Current Assets	16.2b	21.2b	16.9b	49.5b	24.2b
PP&E	2.6b	2.8b	2.9b	3.0b	5.2b
Goodwill	15.4b	15.8b	15.7b	15.6b	33.1b
Total Assets	66.1b	70.8b	59.4b	89.1b	150.6b
Accounts Payable	9.4b	10.2b	1.5b	11.8b	20.2b
Short-term debt	402.0m	6.4b	5.3b	3.8b	8.5b
Current Liabilities	9.8b	16.6b	17.2b	15.6b	28.7b
Long-term debt	36.4b	31.0b	35.0b	63.0b	77.6b
Total Debt	36.8b	37.4b	40.3b	66.7b	86.1b
Common Stock	18.0m	18.0m	18.0m	18.0m	18.0m
Additional Paid-in Capital	13.7b	14.3b	14.8b	15.2b	17.4b
Retained Earnings	4.4b	5.5b	3.4b	4.7b	1.1b
Total Equity	4.6b	5.1b	(8.4b)	(8.2b)	13.1b
Debt to Equity Ratio	7.9 x	7.3 x	-4.8 x	-8.2 x
Debt to Assets Ratio	0.6 x	0.5 x	0.7 x	0.7 x
Financial Leverage	14.3 x	13.9 x	-7 x	-10.9 x	11.5 x

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021
Cash	4.7b	6.1b	8.4b	9.0b	3.5b	8.0b	4.9b	5.2b	10.6b	41.1b	6.0b	7.9b	9.8b	8.5b
Accounts Receivable	4.7b	4.9b	4.9b	5.8b	5.8b	5.8b	5.7b	5.5b	5.5b	6.4b	8.4b	8.4b	9.6b	9.9b
Prepaid Expenses	3.2b	3.3b	2.7b	3.4b	2.7b	2.1b	1.8b	2.3b	2.1b	2.4b	2.8b	3.2b	3.9b	4.1b
Inventories	1.4b	1.6b	1.8b	1.7b	1.6b	1.8b	1.7b	1.9b	1.9b	1.8b	4.1b	3.5b	3.3b	3.4b
Current Assets	15.5b	17.0b	18.9b	20.4b	13.8b	18.5b	14.4b	15.1b	20.2b	51.8b	21.3b	23.0b	26.6b	26.0b
PP&E	2.6b	2.7b	2.7b	2.8b	2.8b	3.0b	2.9b	2.9b	2.9b	3.0b	4.9b	5.0b	5.2b	5.2b
Goodwill	15.5b	15.7b	15.7b	15.9b	15.7b	15.7b	15.6b	15.6b	15.5b	15.6b	42.7b	42.8b	32.3b	32.4b
Total Assets	65.7b	67.0b	68.8b	69.3b	61.6b	66.2b	56.8b	57.1b	59.4b	91.2b	149.5b	149.6b	150.5b	148.0b
Accounts Payable	8.4b	8.8b	9.2b	10.7b	10.7b	11.4b	11.8b	11.3b	12.2b	12.7b	19.3b	19.4b	20.6b	20.8b
Short-term debt	425.0m	3.4b	3.8b	6.4b	6.5b	4.0b	2.1b	5.6b	5.3b	3.8b	5.4b	4.8b	11.3b	7.9b
Current Liabilities	8.8b	12.3b	13.0b	17.1b	17.2b	15.4b	13.9b	16.9b	17.5b	16.5b	24.6b	24.2b	32.0b	28.7b
Long-term debt	36.5b	33.8b	34.0b	30.9b	30.6b	36.5b	35.1b	31.6b	33.1b	63.3b	82.1b	82.3b	74.2b	74.2b
Total Debt	37.0b	37.2b	37.8b	37.3b	37.1b	40.5b	37.1b	37.3b	38.4b	67.0b	87.4b	87.1b	85.5b	82.1b
Common Stock	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m
Additional Paid-in Capital	13.9b	14.0b	14.2b	14.5b	14.6b	14.7b	14.9b	15.0b	15.1b	15.4b	17.0b	17.1b	17.7b	17.9b
Retained Earnings	5.1b	6.0b	6.5b	5.0b	5.5b	6.8b	4.2b	3.4b	3.7b	6.0b	3.1b	3.3b	2.3b	740.0m
Total Equity	5.0b	6.0b	6.7b	3.6b	(3.4b)	(2.9b)	(7.8b)	(8.6b)	(8.2b)	(7.4b)	14.7b	15.3b	13.7b	12.6b
Debt to Equity Ratio	7.4 x	6.2 x	5.7 x	10.5 x	-11 x	-13.9 x	-4.7 x	-4.3 x	-4.7 x	-9 x	5.9 x	5.7 x
Debt to Assets Ratio	0.6 x	0.6 x	0.5 x	0.5 x	0.6 x	0.6 x	0.7 x	0.7 x	0.6 x	0.7 x	0.6 x	0.6 x
Financial Leverage	13.1 x	11.1 x	10.3 x	19.5 x	-18.3 x	-22.7 x	-7.3 x	-6.7 x	-7.2 x	-12.3 x	10.2 x	9.8 x	11 x	11.7 x

Annual

USD	FY, 2016	FY, 2017	FY, 2018	FY, 2019	FY, 2020
Net Income	6.0b	5.3b	5.7b	7.9b	4.6b
Depreciation and Amortization	1.2b	1.5b	1.8b	2.0b	6.5b
Accounts Receivable	(71.0m)	(391.0m)	(591.0m)	(74.0m)	(929.0m)
Inventories	(38.0m)	93.0m	(226.0m)	(231.0m)	(40.0m)
Accounts Payable	(1.2b)	425.0m	190.0m	(1.1b)	1.5b
Cash From Operating Activities	7.0b	10.0b	13.4b	13.3b	17.6b
Purchases of PP&E	(479.0m)	(529.0m)	(638.0m)	(552.0m)	(798.0m)
Cash From Investing Activities	(6.1b)	(274.0m)	(1.0b)	596.0m	(37.6b)
Short-term Borrowings	(29.0m)	22.0m	299.0m	(3.7b)
Long-term Borrowings	(6.0b)	(25.0m)	(6.0b)	(1.5b)	(5.7b)
Dividends Paid	(3.7b)	(4.1b)	(5.6b)	(6.4b)	(7.7b)
Cash From Financing Activities	(3.9b)	(5.5b)	(14.4b)	18.7b	(11.5b)
Net Change in Cash	(3.3b)	4.2b	(2.0b)	32.6b	(31.5b)
Interest Paid	986.0m	1.1b	1.2b	1.8b	2.6b
Income Taxes Paid	3.6b	1.7b		1.4b	1.7b

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021
Net Income	1.7b	3.6b	5.3b	2.8b	4.8b	7.5b	2.5b	3.2b	5.1b	3.0b	2.3b	4.6b	3.6b	4.3b
Depreciation and Amortization	374.0m	753.0m	1.1b	445.0m	888.0m	1.3b	503.0m	1.0b	1.5b	559.0m	264.0m	4.4b	2.2b	4.4b
Accounts Receivable	(34.0m)	(167.0m)	(163.0m)	(681.0m)	(805.0m)	(806.0m)	(316.0m)	(96.0m)	(207.0m)	(1.0b)	(543.0m)	(574.0m)	(866.0m)	(1.2b)
Inventories	71.0m	1.0m	(119.0m)	(71.0m)	(191.0m)	(367.0m)	(128.0m)	(288.0m)	(401.0m)	(107.0m)	(304.0m)	(193.0m)	(187.0m)	(249.0m)
Accounts Payable	(266.0m)	(530.0m)	444.0m	191.0m	12.0m	881.0m	94.0m	(1.3b)	(582.0m)	1.1b	466.0m	1.9b	236.0m	308.0m
Cash From Operating Activities	2.1b	4.1b	7.4b	2.6b	5.5b	10.0b	3.0b	5.5b	10.0b	3.8b	6.9b	12.7b	4.9b	9.8b
Purchases of PP&E	(95.0m)	(221.0m)	(347.0m)	(119.0m)	(233.0m)	(515.0m)	(107.0m)	(235.0m)	(389.0m)	(125.0m)	(302.0m)	(519.0m)	(188.0m)	(383.0m)
Cash From Investing Activities	(684.0m)	(366.0m)	(475.0m)	(447.0m)	240.0m	(723.0m)	(27.0m)	(167.0m)	1.2b	(129.0m)	(35.8b)	(36.9b)	(342.0m)	(584.0m)
Short-term Borrowings	23.0m	23.0m	423.0m	(33.0m)	111.0m	(400.0m)	(200.0m)	(393.0m)	(699.0m)
Long-term Borrowings	(6.0m)	(13.0m)	(18.0m)	(7.0m)	(3.0b)	(5.0b)	(3.0b)	(3.0b)	(3.0b)		(3.8b)	(4.4b)		(3.5b)
Dividends Paid	(1.0b)	(2.1b)	(3.1b)	(1.1b)	(2.7b)	(4.1b)	(1.6b)	(3.2b)	(4.8b)	(1.8b)	(3.5b)	(5.6b)	(2.3b)	(4.6b)
Cash From Financing Activities	(1.8b)	(2.8b)	(3.6b)	(2.5b)	(11.5b)	(10.6b)	(5.4b)	(7.5b)	(7.9b)	(2.4b)	(5.0b)	(7.8b)	(3.2b)	(9.1b)
Net Change in Cash	(360.0m)	988.0m	3.3b	(296.0m)	(5.8b)	(1.3b)	(2.4b)	(2.1b)	3.4b	1.2b	(33.9b)	(32.0b)	1.3b	97.0m

USD	FY, 2016
Debt/Equity	7.9 x
Debt/Assets	0.6 x
Financial Leverage	14.3 x

AbbVie's Patients was reported to be 52 m in FY, 2019.

	FY, 2018	FY, 2019	Mar, 2020	FY, 2020	Aug, 2021
Active Clinical Trials (Oncology)	200
Countries	175	175		70
Exploratory Phase Products (Calico)			8
Exploratory Phase Products (Immunology)			33
Exploratory Phase Products (Neuroscience)			5
Exploratory Phase Products (Oncology)			45
Exploratory Phase Products (Other)			1
Manufacturing Facilities	14	14		24
Manufacturing and R&D Facilities	14
Partners	220
Patent Applications (US)					375
Patents (US)					729
Patient Support Programs (US)	90
Patients	30 m	52 m
Patients Included in Clinical Trials	104 k
Patients Included in Clinical Trials (US)	40 k
Patients Treated (Immunology)	1 m
Phase I Trials Products (Immunology)			2
Phase I Trials Products (Neuroscience)			3
Phase I Trials Products (Oncology)			18
Phase I Trials Products (Other)			1
Phase II Trials Products (Immunology)			6
Phase II Trials Products (Neuroscience)			2
Phase II Trials Products (Oncology)			3
Phase II Trials Products (Other)			2
Phase III Trials Products (Immunology)			11
Phase III Trials Products (Neuroscience)			1
Phase III Trials Products (Oncology)			13
Phase III Trials Products (Other)			1
Preclinical Phase Products (Calico)			2
Preclinical Phase Products (Immunology)			3
Preclinical Phase Products (Oncology)			7
Preclinical Phase Products (Other)			4
Programs	292
Research and Development Centers	8	8		14
Suppliers	51 k
Trademark Applications (US)					90
Trademarks (US)					18

Ethnicity

	Y, 2020
White, percent	66.3%
Hispanic / Latino, percent	8.9%
Black / African American, percent	5.9%
Asian, percent	16.8%
Other	2%

Source: www.abbvie.com, www.abbvie.com

Gender

	Y, 2020	Y, 2019	Y, 2018	Y, 2017
Male (Top Managers), percent	21.7%	21%	21%	20%
Female (Top Managers), percent	11.7%	11.1%	11.2%	12.2%
Male (Management), percent	17%	16.7%	17%	17.1%
Female (Management), percent	16.3%	15.4%	15.1%	15.1%
Male, percent	15.3%	15%	15%	15%
Female, percent	18%	17.1%	17.1%	17.2%
Other		3.5%	3.5%	3.2%